John W Stevens

List of Publications by Year
in descending order

60 papers	2,307 citations	186265 28 h-index	223800 46 g-index
61 all docs	61 docs citations	61 times ranked	3309 citing authors

#	Article	IF	Citations
1	Assurance in clinical trial design. Pharmaceutical Statistics, 2005, 4, 187-201.	1.3	211
2	Remote monitoring after recent hospital discharge in patients with heart failure: a systematic review and network meta-analysis. Heart, 2013, 99, 1717-1726.	2.9	114
3	Preventing the progression to Type 2 diabetes mellitus in adults at high risk: A systematic review and network meta-analysis of lifestyle, pharmacological and surgical interventions. Diabetes Research and Clinical Practice, 2015, 107, 320-331.	2.8	112
4	Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication. British Journal of Surgery, 2012, 99, 1630-1638.	0.3	94
5	Bayesian cost-effectiveness analysis from clinical trial data. Statistics in Medicine, 2001, 20, 733-753.	1.6	87
6	Assessing and comparing costs: how robust are the bootstrap and methods based on asymptotic normality?. Health Economics (United Kingdom), 2003, 12, 33-49.	1.7	83
7	A framework for cost-effectiveness analysis from clinical trial data. Health Economics (United) Tj ETQq1 1 0.784314 rgBT /Overlock 10	1.7	82
8	Extrapolating Survival from Randomized Trials Using External Data: A Review of Methods. Medical Decision Making, 2017, 37, 377-390.	2.4	79
9	Inference for the Cost-Effectiveness Acceptability Curve and Cost-Effectiveness Ratio. Pharmacoeconomics, 2000, 17, 339-349.	3.3	78
10	Systematic review and economic modelling of the clinical effectiveness and cost-effectiveness of art therapy among people with non-psychotic mental health disorders. Health Technology Assessment, 2015, 19, 1-120.	2.8	71
11	A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures. Health Technology Assessment, 2016, 20, 1-406.	2.8	62
12	On estimators of medical costs with censored data. Journal of Health Economics, 2004, 23, 615-625.	2.7	60
13	What is the clinical effectiveness and cost-effectiveness of cytisine compared with varenicline for smoking cessation? A systematic review and economic evaluation. Health Technology Assessment, 2014, 18, 1-120.	2.8	60
14	Clinical effectiveness of bisphosphonates for the prevention of fragility fractures: A systematic review and network meta-analysis. Bone, 2016, 89, 52-58.	2.9	59
15	Bayesian methods for design and analysis of cost-effectiveness trials in the evaluation of health care technologies. Statistical Methods in Medical Research, 2002, 11, 469-490.	1.5	55
16	Prehospital Noninvasive Ventilation for Acute Respiratory Failure: Systematic Review, Network Metaâ€analysis, and Individual Patient Data Metaâ€analysis. Academic Emergency Medicine, 2014, 21, 960-970.	1.8	52
17	Routine Antenatal Anti-D Prophylaxis in Women Who Are Rh(D) Negative: Meta-Analyses Adjusted for Differences in Study Design and Quality. PLoS ONE, 2012, 7, e30711.	2.5	49
18	Pre-hospital non-invasive ventilation for acute respiratory failure: a systematic review and cost-effectiveness evaluation. Health Technology Assessment, 2015, 19, 1-102.	2.8	43

#	Article	IF	Citations
19	Telemonitoring after discharge from hospital with heart failure: cost-effectiveness modelling of alternative service designs. BMJ Open, 2013, 3, e003250.	1.9	41
20	Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model. Health Technology Assessment, 2016, 20, 1-326.	2.8	41
21	Cost-effectiveness of presentation versus delayed troponin testing for acute myocardial infarction. Heart, 2012, 98, 1498-1503.	2.9	40
22	Heart-type fatty acid binding protein as an early marker for myocardial infarction: systematic review and meta-analysis. Emergency Medicine Journal, 2013, 30, 280-286.	1.0	40
23	The probability of cost-effectiveness. BMC Medical Research Methodology, 2002, 2, 5.	3.1	39
24	Bayesian decision procedures for binary and continuous bivariate dose-escalation studies. Pharmaceutical Statistics, 2006, 5, 125-133.	1.3	38
25	Efficacy and Safety of Remacemide versus Carbamazepine in Newly Diagnosed Epilepsy: Comparison by Sequential Analysis. Epilepsy and Behavior, 2002, 3, 140-146.	1.7	37
26	Bayesian decision procedures for dose-escalation based on evidence of undesirable events and therapeutic benefit. Statistics in Medicine, 2006, 25, 37-53.	1.6	37
27	Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis. Health Technology Assessment, 2019, 23, 1-328.	2.8	35
28	Routine echocardiography in the management of stroke and transient ischaemic attack: a systematic review and economic evaluation. Health Technology Assessment, 2014, 18, 1-176.	2.8	34
29	Worldwide relative smoking prevalence among people living with and without HIV. Aids, 2021, 35, 957-970.	2.2	32
30	The 3Mg trial: a randomised controlled trial of intravenous or nebulised magnesium sulphate versus placebo in adults with acute severe asthma. Health Technology Assessment, 2014, 18, 1-168.	2.8	30
31	A Review of Survival Analysis Methods Used in NICE Technology Appraisals of Cancer Treatments: Consistency, Limitations, and Areas for Improvement. Medical Decision Making, 2019, 39, 899-909.	2.4	28
32	Nalmefene for Reducing Alcohol Consumption in People with Alcohol Dependence: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 2015, 33, 833-847.	3.3	27
33	Pharmacological thromboprophylaxis to prevent venous thromboembolism in patients with temporary lower limb immobilization after injury: systematic review and network meta‐analysis. Journal of Thrombosis and Haemostasis, 2020, 18, 422-438.	3.8	27
34	Prevalence of respiratory conditions among people who use illicit opioids: a systematic review. Addiction, 2020, 115, 832-849.	3.3	25
35	How Uncertain is the Survival Extrapolation? A Study of the Impact of Different Parametric Survival Models on Extrapolated Uncertainty About Hazard Functions, Lifetime Mean Survival and Cost Effectiveness. Pharmacoeconomics, 2020, 38, 193-204.	3.3	25
36	Thromboprophylaxis in lower limb immobilisation after injury (TiLLI). Emergency Medicine Journal, 2020, 37, 36-41.	1.0	25

#	Article	IF	Citations
37	An Evaluation of a Bayesian Method of Dose Escalation Based on Bivariate Binary Responses. Journal of Biopharmaceutical Statistics, 2004, 14, 969-983.	0.8	24
38	A note on dealing with missing standard errors in meta‐analyses of continuous outcome measures in WinBUGS. Pharmaceutical Statistics, 2011, 10, 374-378.	1.3	23
39	A Model-Based Economic Evaluation of Biologic and Non-Biologic Options for the Treatment of Adults with Moderately-to-Severely Active Ulcerative Colitis after the Failure of Conventional Therapy. Pharmacoeconomics, 2016, 34, 1023-1038.	3.3	21
40	A review of methods for comparing treatments evaluated in studies that form disconnected networks of evidence. Research Synthesis Methods, 2018, 9, 148-162.	8.7	19
41	Golimumab for the Treatment of Rheumatoid Arthritis After the Failure of Previous Disease-Modifying Antirheumatic Drugs: A NICE Single Technology Appraisal. Pharmacoeconomics, 2013, 31, 653-661.	3.3	18
42	Cost-Effectiveness of Cilostazol, Naftidrofuryl Oxalate, and Pentoxifylline for the Treatment of Intermittent Claudication in People With Peripheral Arterial Disease. Angiology, 2014, 65, 190-197.	1.8	18
43	Different strategies for pharmacological thromboprophylaxis for lower-limb immobilisation after injury: systematic review and economic evaluation. Health Technology Assessment, 2019, 23, 1-190.	2.8	17
44	The Rheumatoid Arthritis Drug Development Model: a case study in Bayesian clinical trial simulation. Pharmaceutical Statistics, 2009, 8, 371-389.	1.3	16
45	Assessing prognosis and prediction of treatment response in early rheumatoid arthritis: systematic reviews. Health Technology Assessment, 2018, 22, 1-294.	2.8	16
46	INCORPORATION OF GENUINE PRIOR INFORMATION IN COST-EFFECTIVENESS ANALYSIS OF CLINICAL TRIAL DATA. International Journal of Technology Assessment in Health Care, 2002, 18, 782-790.	0.5	14
47	Incorporating Genuine Prior Information about Between-Study Heterogeneity in Random Effects Pairwise and Network Meta-analyses. Medical Decision Making, 2018, 38, 531-542.	2.4	14
48	Assessment-Schedule Matching in Unanchored Indirect Treatment Comparisons of Progression-Free Survival in Cancer Studies. Pharmacoeconomics, 2019, 37, 1537-1551.	3.3	12
49	Case study in the Bayesian analysis of a cost-effectiveness trial in the evaluation of health care technologies: Depression. Pharmaceutical Statistics, 2003, 2, 51-68.	1.3	9
50	Using short‐term evidence to predict six‐month outcomes in clinical trials of signs and symptoms in rheumatoid arthritis. Pharmaceutical Statistics, 2009, 8, 150-162.	1.3	8
51	Adalimumab for Treating Moderate-to-Severe Hidradenitis Suppurativa: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 2017, 35, 805-815.	3.3	8
52	NICE work: how NICE decides what we should pay for. British Journal of General Practice, 2010, 60, 7-8.	1.4	4
53	Dexamethasone implant for non-infectious uveitis: is it cost-effective?. British Journal of Ophthalmology, 2019, 103, 1639-1644.	3.9	4
54	Remacemide versus carbamazepine in newly diagnosed epilepsy. Epilepsy and Behavior, 2002, 3, 405-406.	1.7	3

#	Article	IF	Citations
55	Using Evidence from Randomised Controlled Trials in Economic Models: What Information is Relevant and is There a Minimum Amount of Sample Data Required to Make Decisions?. Pharmacoeconomics, 2018, 36, 1135-1141.	3.3	2
56	Uncertainty analysis is inherently Bayesian. Value in Health, 2011, 14, 202-203.	0.3	1
57	Decision‐analysis modelling of the effects of thromboprophylaxis for people with lower limb immobilisation for injury. British Journal of Haematology, 2019, 186, 166-168.	2.5	1
58	<i>Pharmaceutical Statistics</i> 10th anniversary. Pharmaceutical Statistics, 2011, 10, 475-476.	1.3	0
59	Obinutuzumab with Bendamustine for Treating Follicular Lymphoma Refractory to Rituximab: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 2018, 36, 1143-1151.	3.3	0
60	Reply to Thromboprophylaxis in temporary lower limb immobilization: Extrapolate with care. Journal of Thrombosis and Haemostasis, 2020, 18, 519-520.	3.8	0